Skip to main content

06-12-2018 | Breast cancer | Video

KATHERINE trial: Adjuvant trastuzumab emtansine improves invasive disease-free survival versus trastuzumab after neoadjuvant chemotherapy in HER2-positive women

Charles Geyer reports his phase III study findings showing the potential for adjuvant trastuzumab emtansine as a new standard of care in women with HER-2 positive, early breast cancer and residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy (7:56).

Funding for these videos was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland